vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Piedmont Realty Trust, Inc. (PDM). Click either name above to swap in a different company.
Piedmont Realty Trust, Inc. is the larger business by last-quarter revenue ($143.3M vs $83.5M, roughly 1.7× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -31.4%, a 38.2% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 0.4%).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Piedmont Realty Trust, Inc. is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality office properties primarily located in high-growth metropolitan areas across the United States. It serves corporate tenants across multiple industry sectors including technology, professional services, and healthcare, and pursues stable long-term returns for stakeholders via strategic property management and portfolio optimization.
BLLN vs PDM — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $143.3M |
| Net Profit | $5.7M | $-45.0M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | — |
| Net Margin | 6.8% | -31.4% |
| Revenue YoY | 117.4% | 0.4% |
| Net Profit YoY | 138.3% | -27.9% |
| EPS (diluted) | $0.10 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $143.3M | ||
| Q4 25 | — | $142.9M | ||
| Q3 25 | $83.5M | $139.2M | ||
| Q2 25 | — | $140.3M | ||
| Q1 25 | — | $142.7M | ||
| Q4 24 | — | $143.2M | ||
| Q3 24 | $38.4M | $139.3M | ||
| Q2 24 | — | $143.3M |
| Q1 26 | — | $-45.0M | ||
| Q4 25 | — | $-43.2M | ||
| Q3 25 | $5.7M | $-13.5M | ||
| Q2 25 | — | $-16.8M | ||
| Q1 25 | — | $-10.1M | ||
| Q4 24 | — | $-30.0M | ||
| Q3 24 | $-14.9M | $-11.5M | ||
| Q2 24 | — | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -32.9% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | -31.4% | ||
| Q4 25 | — | -30.3% | ||
| Q3 25 | 6.8% | -9.7% | ||
| Q2 25 | — | -12.0% | ||
| Q1 25 | — | -7.1% | ||
| Q4 24 | — | -20.9% | ||
| Q3 24 | -38.8% | -8.3% | ||
| Q2 24 | — | -6.8% |
| Q1 26 | — | $-0.10 | ||
| Q4 25 | — | $-0.34 | ||
| Q3 25 | $0.10 | $-0.11 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | $-0.25 | ||
| Q3 24 | $-1.47 | $-0.09 | ||
| Q2 24 | — | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $2.3M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $1.5B |
| Total Assets | $327.5M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.3M | ||
| Q4 25 | — | $731.0K | ||
| Q3 25 | $195.2M | $3.0M | ||
| Q2 25 | — | $3.3M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | — | $109.6M | ||
| Q3 24 | — | $133.6M | ||
| Q2 24 | — | $138.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | $55.0M | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $1.5B | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | $-239.5M | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $-242.9M | $1.6B | ||
| Q2 24 | — | $1.7B |
| Q1 26 | — | $4.0B | ||
| Q4 25 | — | $4.0B | ||
| Q3 25 | $327.5M | $4.0B | ||
| Q2 25 | — | $4.0B | ||
| Q1 25 | — | $4.0B | ||
| Q4 24 | — | $4.1B | ||
| Q3 24 | — | $4.1B | ||
| Q2 24 | — | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.49× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.36× | ||
| Q2 24 | — | 1.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | 110.3% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $140.6M | ||
| Q3 25 | $13.8M | $35.8M | ||
| Q2 25 | — | $50.1M | ||
| Q1 25 | — | $3.7M | ||
| Q4 24 | — | $198.1M | ||
| Q3 24 | — | $42.9M | ||
| Q2 24 | — | $66.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 110.3% | ||
| Q4 25 | — | — | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
PDM
Segment breakdown not available.
